Entecavir reduces hepatocarcinogenesis in chronic hepatitis B patients

Acta Medica Okayama

Volumn 70, Issue 1, 2016, Pages 1-12

  Yasunaka, Tetsuya ^a   Ikeda, Fusao ^a   Wada, Nozomu ^a   Morimoto, Yuki ^a   Fujioka, Shin ichi ^b   Toshimori, Junichi ^c   Kobashi, Haruhiko ^c   Kariyama, Kazuya ^d   Morimoto, Yoichi ^e   Takayama, Hiroki ^f   Seno, Tomonori ^g   Takaguchi, Koichi ^g   Moriya, Akio ^h   Miyatake, Hirokazu ⁱ   Okamoto, Ryoichi ⁱ   Yabushita, Kazuhisa ^j   Takaki, Akinobu ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

^c Okayama Red Cross Hospital   (Japan)

^d Okayama Citizens Hospital   (Japan)

^e KURASHIKI CENTRAL HOSPITAL   (Japan)

^f Tsuyama Central Hospital   (Japan)

^g KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^h Mitoyo General Hospital   (Japan)

ⁱ HIROSHIMA CITY HOSPITAL   (Japan)

^j Fukuyama City Hospital   (Japan)

more..

Author keywords

Entecavir; Hepatitis B virus; Hepatocellular carcinoma; Lamivudine

Indexed keywords

ANTIVIRUS AGENT; ENTECAVIR; GUANINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AGE; ANALOGS AND DERIVATIVES; BLOOD; COMPARATIVE STUDY; COMPLICATION; FEMALE; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMAN; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED;

AGE FACTORS; ANTIVIRAL AGENTS; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LAMIVUDINE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84962271982     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat (2004) 11: 97-107.
2. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK and Locarnini S: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int (2008) 2: 263-283.
3. Liaw YF, Tai DI, Chu CM, Lin DY, Sheen IS, Chen TJ and Pao CC: Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology (1986) 90: 263-267.
4. Fattovic G, Bortolotti F and Donato F: Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol (2008) 48: 335-352.
5. Tong MJ, Hsien C, Hsu L, Sun HE and Blatt LM: Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology (2008) 48: 1070-1078.
6. Shoji B, Ikeda F, Fujioka S, Kobashi H, Yasunaka T, Miyake Y, Shiraha H, Takaki A, Nouso K, Iwasaki Y and Yamamoto K: Laparoscopic findings of reddish markings predict hepatocellular carcinoma in patients with hepatitis B virus-related liver disease. J Gastroenterol (2010) 45: 1172-1182.
7. Umemura T, Ichijo T, Yoshizawa K, Tanaka E and Kiyosawa K: Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol (2009) 44 Suppl 19: 102-107.
8. Fontana RJ, Hann HW, Wright T, Everson G, Baker A, Schiff ER, Riely C, Anschuetz G, Riker-Hopkins M and Brown N: A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl (2001) 7: 504-510.
9. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, Schiff ER and Brown NA: Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet (1997) 349: 20-22.
10. Yasunaka T, Takaki A, Yagi T, Iwasaki Y, Sadamori H, Koike K, Hirohata S, Tatsukawa M, Kawai D, Shiraha H, Miyake Y, Ikeda F, Kobashi H, Matsuda H, Shinoura S, Yoshida R, Satoh D, Utsumi M, Onishi T and Yamamoto K: Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis. Hepatol Int (2011) 5: 918-926.
11. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen h, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF and Sabbat J: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med (2004) 351: 1521-1531.
12. Eun JR, Lee HJ, Kim TN and Lee KS: Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol (2010) 53: 118-125.
13. Papatheodoridis GV, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, Tzourmakliotis D, Manesis E and Hadziyannis SJ: Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology (2005) 42: 121-129.
14. Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, Wong BC, Fung J, Yuen JC and Lai CL: Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther (2007) 12: 1295-1303.
15. Westland CE, Yang H, Delaney WEt, Gibbs CS, Miller MD, Wulfsohn M, Fry J, Brosgart CL and Xiong S: Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology (2003) 38: 96-103.
16. Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, Borroto-Esoda K and Miller MD: No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology (2014) 59: 434-442.
17. Lok AS and McMahon BJ: Chronic hepatitis B: update 2009. Hepatology (2009) 50: 661-662.
18. Zoutendijk R, Reijnders JG, Brown A, Zoulim F, Mutimer D, Deterding K, Petersen J, Hofmann WP, Buti M, Santantonio T, van Bommel F, Pradat P, Oo Y, Luetgehetmann M, Berg T, Hansen BE, Wedemeyer H and Janssen HL, Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology (2011) 54: 443-451.
19. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N and Kumada H: Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis:a prospective observation of 2215 patients. J Hepatol (1998) 28: 930-938.
20. Kato Y, Nakata K, Omagari K, Furukawa R, Kusumoto Y, Mori I, Tajima H, Tanioka H, Yano M and Nagataki S: Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses. Cancer (1994) 74: 2234-2238.
21. Lo KJ, Tong MJ, Chien MC, Tsai YT, Liaw YF, Yang KC, Chian H, Liu HC and Lee SD: The natural course of hepatitis B surface antigen-positive chronic active hepatitis in Taiwan. J Infect Dis (1982) 146: 205-210.
22. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M and Kumada H: Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology (2013) 58: 98-107.